NASDAQ · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · LARGE CAP
Incyte Corp. INCY
17 fiscal years on record · USD · FY2025 reported · SEC filings only
In brief
What this company does
Written from the business description in INCYTE CORP's annual report to the U.S. Securities and Exchange Commission, filed 10 February 2026. Every sentence was checked against that document before publication.
Growth
USD 5.1B
Revenue, FY2025 · full 17-year series below
Revenue $B
Net income $B
FY2025 · Revenue 5.1 · Net income 1.3
Compound annual growth
Revenue compounded at +14.0% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
25 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 29.5% · Net 25.0%
ROE
FY2025 · ROE 29.9%
Each USD of equity produced 30 cents of profit this year.
The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 5.1 | 4.2 | 3.7 | 3.4 | 3.0 | 2.7 | 2.2 | 1.9 | 1.5 | 1.1 | 0.8 | 0.5 | 0.4 | 0.3 | 0.1 | 0.2 | 0.0 |
| Operating income $B | 1.5 | 0.1 | 0.6 | 0.6 | 0.6 | −0.3 | 0.4 | 0.1 | −0.2 | 0.1 | 0.1 | −0.0 | −0.0 | 0.0 | −0.1 | 0.0 | −0.1 |
| EBITDA $B | 1.6 | 0.2 | 0.7 | 0.6 | 0.6 | −0.2 | 0.5 | 0.2 | −0.2 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | −0.1 | 0.0 | −0.1 |
| Income tax $B | 0.4 | 0.3 | 0.2 | 0.2 | −0.4 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | · | · | · |
| Net income $B | 1.3 | 0.0 | 0.6 | 0.3 | 0.9 | −0.3 | 0.4 | 0.1 | −0.3 | 0.1 | 0.0 | −0.0 | −0.1 | −0.0 | −0.2 | −0.0 | −0.2 |
| Free cash flow $B | · | · | · | 0.9 | 0.6 | −0.3 | 0.6 | 0.3 | −0.2 | 0.2 | 0.1 | −0.0 | 0.0 | −0.1 | −0.2 | 0.1 | 0.0 |
| EPS, diluted $ | 6.41 | 0.15 | 2.65 | 1.52 | 4.27 | −1.36 | 2.05 | 0.51 | −1.53 | 0.54 | 0.03 | −0.29 | −0.56 | −0.34 | −1.49 | −0.26 | −2.06 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | 29.9 | 0.8 | 12.5 | 8.4 | 29.7 | −11.4 | 19.8 | 6.2 | −30.5 | 35.3 | 14.6 | · | · | · | · | · | · |
| Shares out B | 0.20 | 0.19 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.21 | 0.21 | 0.19 | 0.19 | 0.17 | 0.16 | 0.13 | 0.13 | 0.12 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Compare
This company against its peers
Incyte Corp.vsIqvia Holdings Inc.Same industry: Services-Commercial Physical & Biological ResearchIncyte Corp.vsAecomSame industry: Services-Commercial Physical & Biological ResearchIncyte Corp.vsBooz Allen Hamilton Holding Corp.Same industry: Services-Commercial Physical & Biological ResearchIncyte Corp.vsIcon PLCSame industry: Services-Commercial Physical & Biological ResearchIncyte Corp.vsGartner Inc.Same industry: Services-Commercial Physical & Biological ResearchIncyte Corp.vsPaychex Inc.Same industry: Services-Commercial Physical & Biological ResearchIncyte Corp.vsTetra Tech Inc.Same industry: Services-Commercial Physical & Biological Research
Provenance
Company facts, as filed
How we verify · 0 failures in 65 reconciliationsAUDITED
Reconciled in 17 of 19 fiscal years. 16 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Commercial Physical & Biological Research
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009